HPV16 infection regulates RASSF1A transcription mediated by p53

Lei,Yueshan; Hu,Chengjun; Xu,Hongxin; Tian,Yihao

doi:10.3892/mmr.2013.1529

HPV16 infection regulates RASSF1A transcription mediated by p53

Authors:
- Yueshan Lei
- Chengjun Hu
- Hongxin Xu
- Yihao Tian
View Affiliations

Affiliations: Department of Anatomy and Embryology, School of Basic Medical Sciences, Wuhan University, Wuhan, Hubei 430071, P.R. China, Department of Cardiology, Renmin Hospital, Wuhan University, Wuhan, Hubei 430060, P.R. China
Published online on: June 17, 2013 https://doi.org/10.3892/mmr.2013.1529
Pages: 413-418

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Human papillomavirus (HPV) 16 infection and RASSF1A expression play important roles in tumor development and progression. However, the precise mechanisms underlying their concerted function in the development of reproductive system tumors still remain to be elucidated. In the present study, we showed that HPV16-E6 selectively upregulates RASSF1A expression via degradation of p53, which interacts with the RASSF1A promoter and regulates apoptosis. Overexpression of p53 triggered a decrease in endogenous RASSF1A in SiHa cells, accompanied by apoptosis. Similarly, knockdown of endogenous HPV16-E6 in SiHa cells with RNA interference (RNAi) led to downregulation of RASSF1A mediated by p53 and the subsequent induction of apoptosis. These findings collectively suggest that HPV16 infection regulates p53-mediated RASSF1A expression and suppresses apoptosis. Moreover, RASSF1A may form an element of the negative autoregulatory feedback loops that act on the HPV16 response and are involved in p53-dependent apoptosis. Our results provide novel insights into the cellular mechanism of tumor development, and present a starting point for the development of novel strategies in cancer treatment and effective diagnosis.

View Figures

View References

1	Doorbar J: Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond). 110:525–541. 2006. View Article : Google Scholar : PubMed/NCBI
2	Tomizawa Y, Kohno T, Kondo H, et al: Clinicopathological significance of epigenetic inactivation of RASSF1A at 3p21.3 in stage I lung adenocarcinoma. Clin Cancer Res. 8:2362–2368. 2002.PubMed/NCBI
3	Dammann R, Li C, Yoon JH, Chin PL, et al: Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet. 25:315–319. 2000. View Article : Google Scholar : PubMed/NCBI
4	Lehmann U, Langer F, Feist H, et al: Quantitative assessment of promoter hypermethylation during breast cancer development. Am J Pathol. 160:605–612. 2002. View Article : Google Scholar : PubMed/NCBI
5	Xing M, Cohen Y, Mambo E, et al: Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. Cancer Res. 64:1664–1668. 2004. View Article : Google Scholar : PubMed/NCBI
6	Yegnasubramanian S, Kowalski J, Gonzalgo ML, et al: Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 64:1975–1986. 2004. View Article : Google Scholar : PubMed/NCBI
7	Kuzmin I, Liu L, Dammann R, et al: Inactivation of RAS association domain family 1A gene in cervical carcinomas and the role of human papillomavirus infection. Cancer Res. 63:1888–1893. 2003.PubMed/NCBI
8	Cohen Y, Singer G, Lavie O, et al: The RASSF1A tumor suppressor gene is commonly inactivated in adenocarcinoma of the uterine cervix. Clin Cancer Res. 9:2981–2984. 2003.PubMed/NCBI
9	Kim SH, Juhnn YS, Kang S, et al: Human papillomavirus 16 E5 up-regulates the expression of vascular endothelial growth factor through the activation of epidermal growth factor receptor, MEK/ERK1,2 and PI3K/Akt. Cell Mol Life Sci. 63:930–938. 2006. View Article : Google Scholar : PubMed/NCBI
10	Tan S, Hougardy BM, Meersma GJ, et al: Human papilloma virus 16 E6 RNA interference enhances cisplatin and death receptor-mediated apoptosis in human cervical carcinoma cells. Mol Pharmacol. 81:701–709. 2012. View Article : Google Scholar
11	Vassallo J, Derchain SF, Pinto GA, Martinez EZ, Syrjänen KJ and Andrade LA: High risk HPV and p53 protein expression in cervical intraepithelial neoplasia. Int J Gynaecol Obstet. 71:45–48. 2000. View Article : Google Scholar : PubMed/NCBI
12	Tian Y, Hou Y, Zhou X, et al: Tumor suppressor RASSF1A promoter: p53 binding and methylation. PLoS One. 6:e170172011. View Article : Google Scholar : PubMed/NCBI
13	Preethy CP, Padmapriya R, Periasamy VS, et al: Antiproliferative property of n-hexane and chloroform extracts of Anisomeles malabarica (L). R Br in HPV16-positive human cervical cancer cells. J Pharmacol Pharmacother. 3:26–34. 2012. View Article : Google Scholar : PubMed/NCBI
14	Matallanas D, Romano D, Yee K, et al: RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. Mol Cell. 27:962–975. 2007. View Article : Google Scholar
15	Shivakumar L, Minna J, Sakamaki T, et al: The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol Cell Biol. 22:4309–4318. 2002. View Article : Google Scholar : PubMed/NCBI
16	Song MS, Song SJ, Ayad NG, et al: The tumour suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex. Nat Cell Biol. 6:129–137. 2004. View Article : Google Scholar : PubMed/NCBI
17	Fen J, Yoshinouchi M, Nakamura K, et al: Eradication of HPV post-surgical treatments, its correlation with specific types, types of surgery and the physical status. Oncol Rep. 12:375–379. 2004.PubMed/NCBI
18	Bosch FX, Manos MM, Muñoz N, et al: Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst. 87:796–802. 1995. View Article : Google Scholar
19	Pöllänen R, Soini Y, Vähäkangas K, et al: Aberrant p53 protein expression in cervical intra-epithelial neoplasia. Histopathology. 23:471–474. 1993.
20	Boulet G, Horvath C, Vanden Broeck D, et al: Human papilloma virus: E6 and E7 oncogenes. Int J Biochem Cell Biol. 39:2006–2011. 2007. View Article : Google Scholar
21	Kuzmin I, Gillespie JW, Protopopov A, et al: The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. Cancer Res. 62:3498–3502. 2002.PubMed/NCBI
22	Rong R, Jiang LY, Sheikh MS, et al: Mitotic kinase Aurora-A phosphorylates RASSF1A and modulates RASSF1A-mediated microtubule interaction and M-phase cell cycle regulation. Oncogene. 26:7700–7708. 2007. View Article : Google Scholar : PubMed/NCBI
23	Ahmed-Choudhury J, Agathanggelou A, Fenton SL, et al: Transcriptional regulation of cyclin A2 by RASSF1A through the enhanced binding of p120E4F to the cyclin A2 promoter. Cancer Res. 65:2690–2697. 2005. View Article : Google Scholar : PubMed/NCBI
24	Song SJ, Song MS, Kim SJ, et al: Aurora A regulates prome-taphase progression by inhibiting the ability of RASSF1A to suppress APC-Cdc20 activity. Cancer Res. 69:2314–2323. 2009. View Article : Google Scholar : PubMed/NCBI
25	Baksh S, Tommasi S, Fenton S, et al: The tumor suppressor RASSF1A and MAP-1 link death receptor signaling to Bax conformational change and cell death. Mol Cell. 18:637–650. 2005. View Article : Google Scholar : PubMed/NCBI
26	Rabizadeh S, Xavier RJ, Ishiguro K, et al: The scaffold protein CNK1 interacts with the tumor suppressor RASSF1A and augments RASSF1A-induced cell death. J Biol Chem. 279:29247–29254. 2004. View Article : Google Scholar : PubMed/NCBI